541 related articles for article (PubMed ID: 19103570)
1. 3D-QSAR studies for the binding affinity toward (R, S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)-propionic acid receptor.
Sharma RN; Thakar H; Vasu KK; Chaturvedi SC
Acta Pharm; 2008 Sep; 58(3):335-45. PubMed ID: 19103570
[TBL] [Abstract][Full Text] [Related]
2. Pair wise binding affinity: 3D QSAR studies on a set of triazolo [1, 5-a] quinoxalines as antagonists of AMPA and KA receptors.
Sharma RN; Thakar HM; Vasu KK; Chaturvedi SC; Pancholi SS
J Enzyme Inhib Med Chem; 2009 Aug; 24(4):1008-14. PubMed ID: 19548793
[TBL] [Abstract][Full Text] [Related]
3. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
Pandey G; Saxena AK
J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
[TBL] [Abstract][Full Text] [Related]
4. Pharmacophore modeling as an efficient tool in the discovery of novel noncompetitive AMPA receptor antagonists.
Barreca ML; Gitto R; Quartarone S; De Luca L; De Sarro G; Chimirri A
J Chem Inf Comput Sci; 2003; 43(2):651-5. PubMed ID: 12653534
[TBL] [Abstract][Full Text] [Related]
5. QSAR study of a large set of 3-pyridyl ethers as ligands of the alpha4beta2 nicotinic acetylcholine receptor.
Zhang H; Li H; Ma Q
J Mol Graph Model; 2007 Jul; 26(1):226-35. PubMed ID: 17208024
[TBL] [Abstract][Full Text] [Related]
6. Molecular docking and 3D QSAR studies on 1-amino-2-phenyl-4-(piperidin-1-yl)-butanes based on the structural modeling of human CCR5 receptor.
Xu Y; Liu H; Niu C; Luo C; Luo X; Shen J; Chen K; Jiang H
Bioorg Med Chem; 2004 Dec; 12(23):6193-208. PubMed ID: 15519163
[TBL] [Abstract][Full Text] [Related]
7. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
8. Heteroaryl analogues of AMPA. Synthesis and quantitative structure-activity relationships.
Bang-Andersen B; Lenz SM; Skjaerbaek N; Søby KK; Hansen HO; Ebert B; Bøgesø KP; Krogsgaard-Larsen P
J Med Chem; 1997 Aug; 40(18):2831-42. PubMed ID: 9288165
[TBL] [Abstract][Full Text] [Related]
9. 8-(1H-imidazol-1-yl)-7-nitro-4(5H)-imidazo[1,2-alpha]quinoxalinone and related compounds: synthesis and structure-activity relationships for the AMPA-type non-NMDA receptor.
Ohmori J; Shimizu-Sasamata M; Okada M; Sakamoto S
J Med Chem; 1997 Jun; 40(13):2053-63. PubMed ID: 9207947
[TBL] [Abstract][Full Text] [Related]
10. Selectivity fields: comparative molecular field analysis (CoMFA) of the glycine/NMDA and AMPA receptors.
Baskin II; Tikhonova IG; Palyulin VA; Zefirov NS
J Med Chem; 2003 Sep; 46(19):4063-9. PubMed ID: 12954059
[TBL] [Abstract][Full Text] [Related]
11. Pharmacophore-based 3D-QSAR of HIF-1 inhibitors.
Chung JY; Pasha FA; Cho SJ; Won M; Lee JJ; Lee K
Arch Pharm Res; 2009 Mar; 32(3):317-23. PubMed ID: 19387572
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of novel quinoxaline-2,3-dione AMPA/GlyN receptor antagonists: amino acid derivatives.
Nikam SS; Cordon JJ; Ortwine DF; Heimbach TH; Blackburn AC; Vartanian MG; Nelson CB; Schwarz RD; Boxer PA; Rafferty MF
J Med Chem; 1999 Jun; 42(12):2266-71. PubMed ID: 10377233
[TBL] [Abstract][Full Text] [Related]
13. CoMFA and CoMSIA 3D QSAR analysis on N1-arylsulfonylindole compounds as 5-HT6 antagonists.
Doddareddy MR; Cho YS; Koh HY; Pae AN
Bioorg Med Chem; 2004 Aug; 12(15):3977-85. PubMed ID: 15246074
[TBL] [Abstract][Full Text] [Related]
14. 3D-QSAR CoMFA/CoMSIA studies on 5-aryl-2,2-dialkyl-4-phenyl-3(2H)-furanone derivatives, as selective COX-2 inhibitors.
Puntambekar DS; Giridhar R; Yadav MR
Acta Pharm; 2006 Jun; 56(2):157-74. PubMed ID: 16613723
[TBL] [Abstract][Full Text] [Related]
15. 3D-QSAR studies of Checkpoint Kinase Weel inhibitors based on molecular docking, CoMFA and CoMSIA.
Yi P; Fang X; Qiu M
Eur J Med Chem; 2008 May; 43(5):925-38. PubMed ID: 17698256
[TBL] [Abstract][Full Text] [Related]
16. Insight into the structural requirements of proton pump inhibitors based on CoMFA and CoMSIA studies.
Nayana MR; Sekhar YN; Nandyala H; Muttineni R; Bairy SK; Singh K; Mahmood SK
J Mol Graph Model; 2008 Oct; 27(3):233-43. PubMed ID: 18676164
[TBL] [Abstract][Full Text] [Related]
17. Rational design based on bioactive conformation analysis of pyrimidinylbenzoates as acetohydroxyacid synthase inhibitors by integrating molecular docking, CoMFA, CoMSIA, and DFT calculations.
He YZ; Li YX; Zhu XL; Xi Z; Niu C; Wan J; Zhang L; Yang GF
J Chem Inf Model; 2007; 47(6):2335-44. PubMed ID: 17887745
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of analogues of 7-chloro-4,5-dihydro-4- oxo-8-(1,2,4-triazol-4-yl)-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylic acid (TQX-173) as novel selective AMPA receptor antagonists.
Catarzi D; Colotta V; Varano F; Calabri FR; Filacchioni G; Galli A; Costagli C; Carlà V
J Med Chem; 2004 Jan; 47(1):262-72. PubMed ID: 14695840
[TBL] [Abstract][Full Text] [Related]
19. Development of new CoMFA and CoMSIA 3D-QSAR models for anti-inflammatory phthalimide-containing TNFalpha modulators.
Avila CM; Romeiro NC; da Silva GM; Sant'Anna CM; Barreiro EJ; Fraga CA
Bioorg Med Chem; 2006 Oct; 14(20):6874-85. PubMed ID: 16843662
[TBL] [Abstract][Full Text] [Related]
20. CoMFA and homology-based models of the glycine binding site of N-methyl-d-aspartate receptor.
Tikhonova IG; Baskin II; Palyulin VA; Zefirov NS
J Med Chem; 2003 Apr; 46(9):1609-16. PubMed ID: 12699379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
